New York Jets running back Breece Hall sat out practice Wednesday with an injured knee and it's uncertain if he'll play Sunday against Seattle. Interim coach Jeff Ulbrich said Hall hurt the knee in the Jets’ 28-27 loss to the Indianapolis Colts on Nov. 17, but was able to finish the game. Hall experienced some soreness, so the team is being cautious with its leading rusher. “We’re going to protect him from himself a little bit today, but we’ll see how the week goes along,” Ulbrich said. “Still hopeful that he’s going to play for us, but we’ll see.” Hall has 632 yards rushing and four touchdowns, along with 46 catches for 401 yards and two scores for the Jets, who were holding their first full practice since returning from their bye-week break. Rookies Braelon Allen and Isaiah Davis would likely fill in if Hall can't play. Left tackle Tyron Smith remains sidelined with a neck injury and Ulbrich acknowledged Smith could be a candidate for the injured reserve list. Smith, in his first season with New York after 13 in Dallas, missed the game against the Colts after leaving the Jets' loss in Arizona with the neck injury. Rookie Olu Fashanu would be in line to start again in Smith's place. “Just not enough improvement at this point,” Ulbrich said of Smith. “It’s really become apparent that we might have to do what’s best for Tyron in that way. But (we're) still collecting information.” Ulbrich said Smith, whose injury hasn't been specified, has been splitting his time between being at the facility and having exams elsewhere. “He's getting stuff done,” Ulbrich said. “He's got the best doctors on Earth working with him.” The Jets could get linebacker C.J. Mosley back from a herniated disk in his neck that sidelined him the past four games. Mosley, who was injured during pregame warmups on Oct. 27, fully practiced Wednesday. “He's going to give it a run,” Ulbrich said before practice. “We're going to see what it looks like. ... And then tomorrow will be the big test. You know, get pads on him, get him to contact and see how he responds with that. If things go well, which I’m hopeful they will, he’ll go. If not, he won’t.” Wide receiver Malachi Corley didn't practice because of an illness and cornerback Quan'tez Stiggers was out for personal reasons. Offensive lineman Xavier Newman was limited after having his practice window opened. Newman has been on injured reserve since hurting his neck at Pittsburgh last month and being taken to the hospital. AP NFL: https://apnews.com/hub/NFLThe Giants were a no-show against the Bucs after releasing quarterback Daniel JonesJudge rejects request to sideline a San Jose State volleyball player on grounds she’s transgenderStockhead Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. When we were kids eyeing an unobtainable treat or the not-so-imminent arrival of Santa, Mum used to tell us to be patient. Patience, indeed, is a virtue and an admirably quality to exhibit throughout one’s adult life. But there are circumstances when even a Job-like quotient of patience will not suffice – and one of them is waiting for the effect of erectile dysfunction tablets to kick in. According to LTR Pharma, oral drugs such as Viagra and Cialis can take more than an hour to have their desired effects. Yes, there’s such a thing as foreplay but in such a time span the amorous vibe is likely to be surpassed by the imperative of vacuuming the hall or emptying the dishwasher. LTR Pharma is developing a nasally-delivered variant of the same drug class which, on evidence to date, hits peak bloodstream levels within nine to 15 minutes. LTR founder and executive chair Lee Rodne says 50% of men stop taking the current tablets within a year, because of the timing problem and side effects. “A lot of guys don’t realise that Viagra is very variable as a tablet because of the delivery mechanism,” Rodne says. “It has to go through your gut and your liver; sometimes it is effective but sometimes it is not effective at all.” The rise and rise of LTR Rodne founded LTR based on technology acquired from California’s Strategic Drug Solutions, with pharmacologist Prof Moses Chow credited as the inventor. Then an executive with iron-ore producer Fortescue Metals, Rodne was hand-picked by Fortescue founder Dr Andrew ‘Twiggy’ Forrest to lead the company’s health spin-off Allied Medical. Rodne led Allied for 10 years, merging it with Biomd to become Allied Healthcare and then Admedus and now heart transcatheter play Anteris Technologies. Rodne’s Allied experience led him to a group of medical researchers and manufacturers who asked him for help with a project to make erectile dysfunction treatments more effective and consistent. Under the deal with Strategic Drug Solutions, LTR Pharma can use the technology in any way, but its current sole focus is on erectile dysfunction (ED). LTR Pharma listed on December 11 last year, having raised $7 million at 20 cents apiece. Rodne owns 34% of the company, with fellow director Dr Julian Chick accounting for 19.7%. Chick has been involved in no fewer than 16 start-ups and helmed the ASX-listed Avexa, which tried to develop an HIV drug but eventually went coal mining in Alabama instead. He is the chair of pot play Cann Group and is behind the impending ASX listing of a nerve-regeneration company called Renerve. About Spontan Spontan – as in spontaneous – is a drug and device combination to deliver vardenafil, the basis of Levitra and Staxyn. Vardenafil is a PDE5 inhibitor, which target receptors that relax muscles and increase blood flow to the penis. Other PDE5 inhibitors are behind Pfizer’s Viagra (sildenafil), the first to market in 1998, Cialis (tadalafil) and Stendra (avanafil). All these PDE5s are pretty much same-same, but vardenafil was deemed the most suitable for nasal reformulations. Rodne says current side-effects include heartburn and joint pain, which are all the result of the oral tablets going through the gastro-intestinal tract. Spontan, of course, goes straight to the blood stream. Why not earlier? Rodne says Spontan currently faces no competition, but the lingering question is why big pharma - notably trailblazer Pfizer with its ‘Pfizer riser’ - didn’t crack the nasal channel. Cialis, Viagra and Levitra, the three biggest-selling erectile dysfunction drugs are now off-patent and subject to generic competition. Stendra’s patent expires in April 2025. “Pfizer looked into it but it’s very hard to work because of the chemical structure,” he says. “It tends crystallise when in liquid form, so you can’t just crush up a chemical tablet, put it in a bottle and expect to be able to spray it.” The nub of LTR’s smarts is the ability to keep the drug soluble and enhance drug interaction. Where’s the evidence? LTR Pharma’s proof of efficacy to date is a small local trial and ‘real world’ usage evidence. On June 7 this year the company said an 18-man bio-availability trial showed Spontan hit peak bloodstream levels in nine to 15 minutes – an average of 12 minutes – compared with an average 56 minutes and as much as 150 minutes for oral vardenafil. The healthy adults were given two single 5.0mg doses of Spontan, as well as a 10mg dose of the oral version after a respectable crossover period. Given the drug is known to be effective once it reaches the bloodstream, that’s all the trial had to prove. In other words, the subjects weren’t being assessed on the quality of erections and lovemaking by a white-coated researcher at the end of the bed. Early in the piece, LTR became eligible for the local Therapeutics Goods Administration’s special access scheme and then the authorised prescriber scheme. These allow unapproved treatments to be administered. Initially, Spontan was prescribed by two men’s health doctors, but has spread to a broader cohort. A notable prescriber is urology expert Prof Eric Chung of the University of Queensland. Taking it slowly Rodne says the company won’t reveal current patient use – which is on the rise – because it doesn’t want investors to focus on sales for what is still a research and development-stage company transitioning to commercial phase. “Before we do that fully, we want specific feedback on patient use, such as whether they are using it in combination with other products,” he says. “We also want to produce education videos on how to use the product and we have some more packaging work to do and ensure patients can follow the instructions clearly.” That said, the company hopes the trial and the real-world data will support a marketing application to the TGA initially and the US Food and Drug Administration in early to mid-2025. The FDA filing is expected to be under the 505(b)(2) route, pertaining to a “change in route of administration for already approved drug”. “We expect to use the data packages for both agencies, but our home market is important for us,” Rodne says. While the requirement for further trials is unclear, the company expects more investigator-led studies here, with a standard requirement for an animal toxicology study. Take your partners In the meantime, LTR is in confidential licensing and partnering discussions with pharmaceutical companies. “We will run these discussions until 2025 and see what sort of value we can create,” Rodne says. “They would not waste their time if they were not interested.” In mid-August, LTR entered a co-development agreement with the New York-listed Aptar Pharma, a developer of nasal spray medicines used by drug companies including Pfizer and Johnson & Johnson. “They don’t partner with everyone: it needs to be a differentiated product with a big market and significant data.” As LTR’s device partner, Aptar will carry out market and regulatory readiness work, such as meeting with the agencies and formulation studies. “Aptar has more than 25 products approved with the FDA, so we don’t have to prove in the same way we don’t have to prove the drug works, because it has already been approved in oral form.” Indeed, the PDE5 tablets have been tested on hundreds of thousands – if not millions - of patients and cost more than US$1 billion to develop. Telehealth Earlier this month, LTR entered a joint venture with a West Australian men's health group, the Restorative Sexual Health Clinic, for an online healthcare platform. “The online platform will provide a discrete and convenient channel for men to access professional healthcare services and prescribed treatments,” Rodne says. The platform is expected to launch in the March quarter of next year. Finances and performance Shortly after the positive trial results, LTR bolstered its $7 million of IPO funds with a $10.5 million placement, struck at 73 cents apiece (a 19% discount). Rodne says LTR has sufficient cash – three years – beyond the likely timelines for regulatory approval and commercial partnering. The company intends to devote some of the funds to building an online sales channel, to avail of the rapid rise in digital prescriptions (in fact, the lion’s share of erectile dysfunction scripts is written remotely). LTR Pharma’s annual report shows a contingent liability of US$3 million, by way of potential milestone payments to Strategic Drug Solutions. LTR Pharma shares have always traded above their 20 cents listing price, bottoming at 27 cents two days after the IPO and peaking at $2.06 on October 10 this year. Dr Boreham’s diagnosis Rodne says that as a company focused on a single re-purposed drug, LTR Pharma is a simple story to understand. Spontan also addresses a high unmet need, with an estimated 322 million of the world’s blokes estimated to suffer erectile difficulties. Of these, close to half are in China, which might explain the nation’s sagging birth rate. Australian blokes can’t exactly stand proud, either, with the condition affecting more than 60% of over 45s. The value of the erectile dysfunction market is estimated at US$4.52 billion, with the US accounting for 30% despite having less than 10% of the sufferers. The market is expected to grow to US$6 billion by 2028, despite what Rodne describes as a complete lack of erectile dysfunction treatment innovation. While LTR Pharma is an easy-to-understand proposition, there’s no plan B if Spontan fails to gain market approval or flops at launch. An unexpected rival could also emerge, but Rodne believes the coast is clear. The endgame for LTR is unclear – it might go all the way to market on its own – but it would be stiff for the company to fail at this point. After all, Spontan would seem to be a great way for, say, Pfizer, to re-establish patent life on its famed blue pill. At a glance ASX code: LTP Share price: $1.205 Shares on issue: 153,901,979 Market cap: $102.17 million Executive chair: Lee Rodne Board: Rodne, Dr Julian Chick, Maja McGuire Financials (year to June 30, 2024): revenue nil, loss of $9.95 million ($1.45 million deficit previously), cash of $3.1 million (up 79%) ahead of $10.5 million capital raising Identifiable major shareholders: Rodne 34% interest, Strategic Drug Solutions 3.8%, Trexapharm 2.7%. Disclosure: Dr Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. He doesn’t have a Job-like quotient of patience, so will ensure the dishwasher stays off at the crucial moment. This column first appeared in Biotech Daily. At Stockhead we tell it like it is. While LTR Pharma is a Stockhead advertiser at the time of writing, it did not sponsor this article. Originally published as Dr Boreham’s Crucible: The rise and rise of LTR Pharma More related stories Stockhead Trump’s tariffs hits ASX, but EML jumps 24pc The ASX has dropped on Tuesday following Trump’s tariff announcement, but EML Payments surged after reporting strong Q1 results. Read more Stockhead Two biotech IPOs test strength of market Two new biotech companies – Vitrafy and Renerve – listed today, breaking an eight-month drought of life sciences IPOs on the ASX. Read morejoli.bet 。

Friend of Quebec man killed in Florida boat explosion says his sister also injuredChina has recently unveiled two significant advancements in its military capabilities, challenging U.S. dominance. On December 26, 2024, China conducted test flights of its new sixth-generation heavy stealth fighter jet, featuring a tailless design aimed at enhancing stealth and maneuverability. Following this, on December 27, 2024, China launched the Type 076 amphibious assault ship, named Sichuan, at a shipyard in Shanghai. ET Year-end Special Reads Take That: The gamechanger weapon's India acquired in 2024 10 big-bang policy moves Modi government made in 2024 How governments tried to rein in the social media beast Key Features of the Type 076 Amphibious Assault Ship The Sichuan has a full-load displacement exceeding 40,000 tons, ranking it among the world's largest amphibious assault ships. Its expansive design allows for the accommodation of various aircraft and equipment. Equipped with a full-length flight deck and a twin-island superstructure, the ship can operate both fixed-wing aircraft and helicopters, enhancing its versatility in military operations. A notable feature of the Sichuan is its electromagnetic catapult system, enabling the launch of larger and heavier aircraft directly from its deck. This technology improves the ship's operational range and firepower, aligning with modern naval warfare requirements. Also Read: DOGE Federal Budget Overhaul: Musk and Ramaswamy’s $2 Trillion Plan to Transform Government Spending Strategic Implications of Recent A dvancements The introduction of the Type 076 amphibious assault ship signifies a substantial enhancement of China's naval power. This development is part of a broader strategy to bolster maritime capabilities and project power beyond its shores, potentially challenging the naval dominance of other global powers. Also Read : Apple Pulls iPhone 14 and SE from Europe as USB-C Mandate Changes the Game FAQs: What is the Type 076 amphibious assault ship? The Type 076 is China's latest amphibious assault ship, launched on December 27, 2024, in Shanghai. Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Basics of Generative AI: Unveiling Tomorrows Innovations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Master in Python Language Quickly Using the ChatGPT Open AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Performance Marketing for eCommerce Brands By - Zafer Mukeri, Founder- Inara Marketers View Program Office Productivity Zero to Hero in Microsoft Excel: Complete Excel guide 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance A2Z Of Money By - elearnmarkets, Financial Education by StockEdge View Program Marketing Modern Marketing Masterclass by Seth Godin By - Seth Godin, Former dot com Business Executive and Best Selling Author View Program Astrology Vastu Shastra Course By - Sachenkumar Rai, Vastu Shashtri View Program Strategy Succession Planning Masterclass By - Nigel Penny, Global Strategy Advisor: NSP Strategy Facilitation Ltd. View Program Data Science SQL for Data Science along with Data Analytics and Data Visualization By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) AI and Analytics based Business Strategy By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Artificial Intelligence(AI) AI-Powered Python Mastery with Tabnine: Boost Your Coding Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital marketing - Wordpress Website Development By - Shraddha Somani, Digital Marketing Trainer, Consultant, Strategiest and Subject Matter expert View Program Office Productivity Mastering Google Sheets: Unleash the Power of Excel and Advance Analysis By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Mastering Full Stack Development: From Frontend to Backend Excellence By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Financial Literacy i.e Lets Crack the Billionaire Code By - CA Rahul Gupta, CA with 10+ years of experience and Accounting Educator View Program Data Science SQL Server Bootcamp 2024: Transform from Beginner to Pro By - Metla Sudha Sekhar, IT Specialist and Developer View Program What is the new Chinese sixth-generation stealth fighter jet? On December 26, 2024, China conducted test flights of its new sixth-generation heavy stealth fighter jet. The jet features a tailless design aimed at enhancing stealth and maneuverability. (You can now subscribe to our Economic Times WhatsApp channel )

Heavy fog impacts dozens of flights at Melbourne AirportLuke Williams feels Swansea ‘lost grip’ on game despite sealing victory at Derby(The Center Square) – Christians helped push President-elect Donald Trump across the finish line on Election Day, a survey found. Trump received the majority of the Christian vote, while Vice President Kamala Harris received the majority of the non-Christian vote. This is according to a report from the Cultural Research Center at Arizona Christian University, which surveyed 2,000 voting-age adults nationally. The election was a historic comeback for Republicans on many fronts, with Trump being the first Republican to win the popular vote vote in over two decades. Among self-identified Christians, Trump also received 56% of their votes, compared to the 60% Harris received from non-Christians. Yet, because the majority of voters still identify as Christians, Trump had a larger share of the vote. “Although Harris won a larger share of the non-Christian vote than Trump’s share of the Christian votes, Christians outnumbered non-Christian voters by more than a 5 to 2 margin – delivering the decisive Nov. 5 victory to President Trump,” the report said. “Not only did most of Trump’s votes come from Christians, but they gave him a 17 million vote cushion over Harris, which proved to be an insurmountable lead.” Christians represented 72% of the voters who turned out. The report also found that Catholics had record-high turnout, despite overall voter and Christian voter turnout being well below what it was in 2020. While voter turnout was lower than 2020 in most of the Christian subgroups polled, 70% of Catholics reported voting compared to 2020’s 67%. Voters with a “biblical worldview” also voted at a higher percentage, up to 67% in 2024 from 2020’s 64%. Just days before the election, Trump predicted that Harris would struggle with the Catholic vote on Election Day. “Kamala Harris has finally lost the Catholic vote,” he said on social media on Oct. 25. “Her and the Democrats persecution of the Catholic Church is unprecedented! Her poll numbers have dropped like a rock, both with Catholics, and otherwise.” While many politicos expressed concerns that Trump’s moderate pro-life stance would disenfranchise Christian and anti-abortion voters, it seems to have much less of an impact than expected. In fact, Trump pointed to Harris’ abortion stance as pushing Catholics toward voting for him. “Kamala is demanding late-term abortion, in months seven, eight, and nine, and even execution after birth, and people aren’t buying it – and they never will,” the former president said . The report found that 20% of Christians selected abortion as the most-consequential issue this election, with inflation (38%) and immigration (34%) receiving even higher percentages. Yet, potentially even more impactful on the election than the increase in the Catholic vote was the significant drop in non-Christian turnout, even higher than those reported in Christian subgroups. The report found that adults “associated with a faith other than Christianity” and “adults who have no religious faith” had a massive drop in turnout from 2020, dropping 12% and 9% respectively. With both of these groups historically supporting Democratic candidates, this cratering in support likely had a significant impact on Harris’ chances of winning. George Barna, who serves as the director of research at the Cultural Research Center and led the survey, said Trump’s boost with Christians was just too much for Harris. “Americans forget that two-thirds of adults in this nation consider themselves to be Christians,” Barna said . “Donald Trump, for all of his perceived and ridiculed faults, did a better job than did Kamala Harris of representing hallowed Christian characteristics such as the importance and support of family, the rule of law, limited government authority, financial responsibility, and the like.”

Stock Surges and Slumps. The Winners and Losers of 2024Cowboys set for Thanksgiving visit from Giants after ending 5-game losing streak

None

Gourmet Market sets out expansion plansHyderabad : The Telangana Anti-Narcotics Bureau (TGNAB), on Saturday, December 28, kick start the “Drug-Free Wellness” initiative, aimed at empowering teenage students in the state to make informed and healthy choices regarding drug and substance abuse. The TGNAB’s initiative collaborates with Edistys Foundation and Kriyate Edutech. The online awareness programme aims to educate students on the dangers of drugs and substance abuse. TGNAB hopes the programme will empower the vulnerable age group to make responsible life choices. The programme is designed to engage stakeholders including parents and educational institutions to collectively combat the drug menace and create a positive impact on students’ lives. Students who complete the programme will receive a certificate issued jointly by TGANB and other partners. The launch event of the programme was attended by TGNAB director Sandeep Shandilya, who emphasized the critical need to address substance abuse through proactive education and awareness to make drug-free Telangana a reality.Thanksgiving Travel Latest: Airport strike, staff shortages and weather could impact holiday travel

Fox News Flash top sports headlines are here. Check out what's clicking on Foxnews.com. After scoring a goal on Monday, U.S. men's soccer star Christian Pulisic joined the wave of athletes who are pulling out President-elect Trump's "YMCA" dance as a celebration. Pulisic told reporters afterward he "thought it was funny" and said the dance moves were not "political" in nature. But that didn't save him from scrutiny. CLICK HERE FOR MORE SPORTS COVERAGE ON FOXNEWS.COM Christian Pulisic and Megan Rapinoe. (Getty Images/IMAGN) The U.S. Soccer Federation (USSF) did not address Pulisic’s dance, but cut that part of the clip out when reposting the score on its social media accounts. However, anonymous USSF officials expressed dismay to The Athletic on Tuesday. "Literally nobody here is surprised," a USSF employee told the outlet . "It doesn’t feel that way, at least. But it’s still really disappointing, to say the least." Another employee added that the organization has "more pressing things to worry about." Well, a former member of the United States men's soccer youth program took a shot at the media for ripping Pulisic, posting a story by The Athletic that was headlined, "Christian Pulisic, the Donald Trump dance and why true leaders consider the impact of their actions." The United States' Christian Pulisic brings the ball down the pitch as Jamaica's Tayvon Gray gives chase during their CONCACAF Nations League quarterfinal second leg soccer match at CityPark in St. Louis on Monday. (AP Photo/Jeff Roberson) "Megan Rapinoe shouts and screams about every radical liberal idea and the soccer media claps like seals at her. Christian Pulisic does the trump dance and now the soccer media says he should worry about what ‘message’ it sends," Andrew Carleton wrote on X on Wednesday . In the story, The Athletic writer Jeff Reuter also warned the soccer star to "consider the impact" of the dance move and why he "may come to regret" it. United States forward Christian Pulisic controls the ball as Jamaica midfielder Joel Latibeaudiere defends during their CONCACAF Nations League quarterfinal second leg soccer match at CityPark in St. Louis on Monday. (Jeff Curry-Imagn Images) "Pulisic can dance if he wants to. Any fan of 1980s one-hit wonders knows that. But it’s one thing to say you’re a leader and another to do what leaders do: consider how their actions will be perceived by their teammates and others," he wrote. "And yes, that extends to dances — especially when you’re literally mimicking the dance of an elected leader. Rather than any of the countless apolitical shimmies he could have chosen, this was a deliberate reference." CLICK HERE TO GET THE FOX NEWS APP Carleton last played in the United Soccer League for the Las Vegas Lights last year. He was a member of the US U20 team in 2019. Follow Fox News Digital’s sports coverage on X , and subscribe to the Fox News Sports Huddle newsletter .

Non-crime hate incidents ‘dragging police into politics’

Judge rejects request to sideline SJSU volleyball player

'Deeply repulsive': ABC chairman unleashes on Joe RoganOntario supports Ottawa's GST holiday, will not ask for lost revenue back

By Ja'han Jones Rapper Sean “Diddy” Combs name-checked Donald Trump in his latest attempt to secure bail amid his ongoing sex trafficking case. And federal prosecutors aren’t feeling it. On Monday, Combs’ attorneys filed a letter affirming their belief that his request for bail should be granted. This was required by Judge Arun Subramanian after prosecutors claimed that Combs should be denied bail because he was allegedly trying to to manipulate witnesses from jail and influence potential jurors . The letter says Combs is “not required to sit idly by” amid a “nonstop drumbeat of negative publicity [that] has destroyed his reputation and will make it virtually impossible for him to receive a fair trial.” The letter continues: He has a right to a fair trial and a constitutional right to speak out on his own behalf. The government’s arguments that asking his children to post birthday wishes on Instagram and that he is not entitled to publicly express his opinion that this prosecution is racially motivated are, quite simply, an unconstitutional effort to silence him. So Combs is seeking the Trump treatment and asking the judge to apply the broad First Amendment protections that the president-elect was afforded in his federal election interference case in Washington. “In United States v. Trump , the D.C. Circuit ‘assume[d] without deciding that the most demanding scrutiny applies to’ pre-trial speech restrictions on criminal defendants, ‘and that only a significant and imminent threat to the administration of criminal justice will support restricting [a defendant’s] speech,’” Combs’ lawyers wrote. Trump, of course, went nuts on social media under his partial gag order in D.C. The lawyers also contend that the judge should apply the Jan. 6 case’s “heightened standard when considering Mr. Combs’ speech here.” Trump, of course, went nuts on social media under his partial gag order in D.C. But prosecutors in the Southern District of New York are raising a seemingly obvious difference between Combs and Trump. In Trump’s case, the court “faced the unique task of balancing the right of a current candidate for the presidency to speak publicly about his charges against the public’s right in a fair trial,” the prosecutors wrote in response Monday. The prosecutors argued that “[t]hose same First Amendment interests are not at stake here,” adding: Further, the defendant’s comments go well beyond attempts to claim that he is innocent of the charges against him and make clear that he intends to use the press to deliberately manipulate “outside influences to be biased in his favor.” The judge is expected to rule on Combs’ latest bail attempt — his third, after two failed tries — sometime this week. As someone who has written about the disturbing similarities between Combs and Trump , it comes as no surprise that the former is now adopting the latter’s legal strategy. Ja'han Jones is The ReidOut Blog writer. He's a futurist and multimedia producer focused on culture and politics. His previous projects include "Black Hair Defined" and the "Black Obituary Project."NoneShedeur Sanders is using his cleats to send a message about the NFL Draft. Sanders’ Colorado Buffaloes were set to face the BYU Cougars at the Alamo Bowl on Saturday, and a photo on social media showed Sanders’ locker for the game. In front of Shedeur’s locker were red shoes with blue. The cleats were New York Giants colors, which seemed to tip off where Sanders thinks he will go as a pro. “We know where we going....You’ll see them in the cleats later on this week” – Shedeur Sanders 3 days ago New York Giants ? pic.twitter.com/AtldiFrgGO — We Coming (@SkoBuffsGoBuffs) December 28, 2024 Earlier in the week, a video had shown Shedeur talking with his brother, Shilo, about the NFL Draft. In the video, Shedeur said, “we know where we going....You’ll see them in the cleats later on this week.” Shilo told Shedeur that a NFL team might trade up for him Shedeur : “You can’t get higher than 1” : @DeionSandersJr pic.twitter.com/3CvtZoWPzn — We Coming (@SkoBuffsGoBuffs) December 25, 2024 There was some previous chatter suggesting Deion preferred for his son to be drafted by the Las Vegas Raiders . But with the Giants now in position to draft No. 1 overall, it seems like Shedeur is completely on board with going to the Big Apple. This article first appeared on Larry Brown Sports and was syndicated with permission.

Wendy’s closure surprise to employees

A regional council has sacked its chief executive officer in a stunning move, dumping the local government leader after a decade of service. Black Friday Sale Subscribe Now! Login or signup to continue reading All articles from our website & app The digital version of Today's Paper Breaking news alerts direct to your inbox Interactive Crosswords, Sudoku and Trivia All articles from the other regional websites in your area Continue Yass Valley Council called an extraordinary meeting earlier this week where councillors voted to sack Chris Berry with immediate effect. The council's director of planning and environment Julie Costa will be the acting CEO until a full-time replacement is found. Yass mayor Jasmin Jones said it would be "business as usual" for ratepayers and residents, but did not give a reason for promptly sacking the former chief. "For our customers, residents and ratepayers, it will be business as usual, and I can assure our community that there will be no interruptions to service delivery during this transition period," Cr Jones in a statement. "Our councillors, management and staff remain firmly focused on improving council's financial performance and achieving positive outcomes for our customers and community." An aerial view of Yass. Picture Yass Valley Council. According its website, Mr Berry had worked for the council since 2014, including a stint as planning director. The Yass council website trumpets Mr Berry's achievements during his tenure. "Chris has risen to the challenge associated with growth in the local government area and the pressures associated with our close proximity to Canberra," his council profile reads. READ MORE: Authorities promise Thursday will be better, after MyWay+ rollout 'teething issues' The APS's biggest bullies revealed Like smoking 15 cigarettes a day " Some of his biggest achievements have been the completion of the settlement strategy for the future growth of Yass valley and finalising the rural lands planning proposal." He was previously general manager of the neighbouring Goulburn council. Earlier this month, Goulburn Mulwaree Council's CEO Aaron Johansson quit, citing an untenable relationship with the mayor Nina Dillon. He cited "differences of opinion" between himself and the mayor over the health of council finances as a key reason. But "multiple factors" played a role. Share Facebook Twitter Whatsapp Email Copy Jacob McArthur Producer Jacob McArthur is opinions editor for The Canberra Times and Australian Community Media. As part of the Canberra Times' production team, he helps the people of Canberra and beyond get the stories they need, when they need them across a range of platforms, while helping maintain a high editorial standard. Before moving to Canberra in 2020, he started with Australian Community Media in 2015 as a journalist for The Northern Daily Leader in Tamworth where he kept a close eye on Tamworth Regional Council. Jacob was also the co-host of ACM's Water Pressure podcast where he and Jamieson Murphy took a deep dive on issues and key decisions arising during one of the region's worst droughts on record. Jacob McArthur is opinions editor for The Canberra Times and Australian Community Media. As part of the Canberra Times' production team, he helps the people of Canberra and beyond get the stories they need, when they need them across a range of platforms, while helping maintain a high editorial standard. Before moving to Canberra in 2020, he started with Australian Community Media in 2015 as a journalist for The Northern Daily Leader in Tamworth where he kept a close eye on Tamworth Regional Council. Jacob was also the co-host of ACM's Water Pressure podcast where he and Jamieson Murphy took a deep dive on issues and key decisions arising during one of the region's worst droughts on record. More from Canberra Gladiator II vs Wicked: How 'Glicked' is bringing back Barbenheimer buzz 17m ago Council abruptly sacks chief, but it's 'business as usual', says mayor 32m ago No comment s Authorities promise Thursday will be better, after MyWay+ rollout 'teething issues' No comment s We could ease cost-of-living pain on poorer households, but it would be awkward No comment s 'Extraordinary' scale of leaders' phone hacks spark warnings for lead-up to election No comment s Raiders tap into Storm success as coaching set-up reshuffled No comment s Newsletters & Alerts View all DAILY Your morning news Today's top stories curated by our news team. Also includes evening update. Loading... WEEKDAYS The lunch break Grab a quick bite of today's latest news from around the region and the nation. Loading... DAILY Sport The latest news, results & expert analysis. Loading... WEEKDAYS The evening wrap Catch up on the news of the day and unwind with great reading for your evening. Loading... WEEKLY Note from the Editor Get the editor's insights: what's happening & why it matters. Loading... WEEKLY FootyHQ Love footy? We've got all the action covered. Loading... DAILY Early Look At David Pope Your exclusive preview of David Pope's latest cartoon. Loading... AS IT HAPPENS Public Service News Don't miss updates on news about the Public Service. Loading... WEEKLY Explore Travel Every Saturday and Tuesday, explore destinations deals, tips & travel writing to transport you around the globe. Loading... WEEKLY Property Get the latest property and development news here. Loading... WEEKLY What's On Going out or staying in? Find out what's on. Loading... WEEKLY Weekend Reads We've selected the best reading for your weekend. Loading... WEEKLY Times Reader's Panel Join our weekly poll for Canberra Times readers. Loading... WEEKDAYS The Echidna Sharp. Close to the ground. Digging deep. Your weekday morning newsletter on national affairs, politics and more. Loading... TWICE WEEKLY The Informer Your essential national news digest: all the big issues on Wednesday and great reading every Saturday. Loading... WEEKLY Motoring Get news, reviews and expert insights every Thursday from CarExpert, ACM's exclusive motoring partner. Loading... TWICE WEEKLY Voice of Real Australia Get real, Australia! Let the ACM network's editors and journalists bring you news and views from all over. Loading... AS IT HAPPENS Breaking news alert Be the first to know when news breaks. Loading... DAILY Today's Paper Alert Your digital replica of Today's Paper. Ready to read from 5am! Loading... DAILY Your favourite puzzles Test your skills with interactive crosswords, sudoku & trivia. Fresh daily! Loading...Angel 5-11 0-0 12, Bittle 4-7 3-4 11, Bamba 7-14 4-7 22, Shelstad 2-8 7-7 12, Tracey 1-3 0-0 2, Barthelemy 5-8 3-5 16, S.Cook 1-4 0-1 2, Evans 0-1 0-0 0, M.Cook 0-0 1-2 1, Moss 0-0 0-0 0. Totals 25-56 18-26 78. Coleman-Jones 1-4 1-2 3, Gwath 1-3 0-0 2, Boyd 6-9 0-1 15, Byrd 4-11 1-1 10, Davis 7-13 2-2 18, DeGourville 2-4 0-0 4, Compton 4-5 0-0 8, McKinney 3-7 0-2 6, Heide 1-1 0-0 2. Totals 29-57 4-8 68. Halftime_Oregon 41-31. 3-Point Goals_Oregon 10-22 (Bamba 4-6, Barthelemy 3-4, Angel 2-5, Shelstad 1-3, Bittle 0-1, Evans 0-1, Tracey 0-2), San Diego St. 6-19 (Boyd 3-4, Davis 2-4, Byrd 1-5, Coleman-Jones 0-1, Gwath 0-1, DeGourville 0-2, McKinney 0-2). Fouled Out_Davis. Rebounds_Oregon 30 (Bittle 9), San Diego St. 22 (Coleman-Jones 6). Assists_Oregon 16 (Bamba 5), San Diego St. 16 (DeGourville 4). Total Fouls_Oregon 16, San Diego St. 21.Bill Clinton Says He Isn't Surprised Donald Trump Won The Election